Price T Rowe Associates Inc Aclaris Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 123,100 shares of ACRS stock, worth $283,130. This represents 0.0% of its overall portfolio holdings.
Number of Shares
123,100
Previous 139,400
11.69%
Holding current value
$283,130
Previous $161,000
90.06%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ACRS
# of Institutions
106Shares Held
87.8MCall Options Held
293KPut Options Held
124K-
Bml Capital Management, LLC Zionsville, IN14.3MShares$32.8 Million21.95% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.63MShares$22.1 Million0.04% of portfolio
-
Vivo Capital, LLC Palo Alto, CA8.89MShares$20.4 Million4.3% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD6.2MShares$14.3 Million0.61% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.67MShares$10.7 Million0.19% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $153M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...